Effects of Chemotherapy Clinical Trial
Official title:
Assessing Fertility Potential in Female Cancer Survivors
Hypothesis: Girls and women exposed to chemotherapy and/or radiation therapy experience endocrine changes more similar to women in their late reproductive years than to same-age peers. These changes will be more dramatic in women who receive high dose therapy compared to women who receive low dose therapy. At annual visits over 3-5 years, a combination of physical exam, medical history, menstrual diary keeping, pelvic ultrasound and blood hormones tests will be used to measure "ovarian reserve" , that is the number and quality of the eggs that remain in the ovaries. The study will also try to learn if those who received higher doses of certain chemotherapies are more likely to have changes in these tests sooner than those women who received smaller doses of these same drugs. Additionally a DNA (deoxyribonucleic acid) sample will be collected to look for gene variations that may predict susceptibility to ovarian damage from cancer treatments. Information learned from this study may help researchers to develop guidelines to identify problems with a female cancer survivor's ovaries before irregular menses or other symptoms of ovarian failure occur.
Up to 400 females will participate in this study in one of three cohorts: - 150 females ages 11-35, with history of exposure to alkylating agent chemotherapy and/or radiation therapy - 150 Unexposed peers, ages 11-35, never exposed to chemotherapy or radiation therapy - 100 Unexposed females, ages 40-50 never exposed to chemotherapy or radiation therapy ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05529940 -
NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)
|
Phase 3 | |
Recruiting |
NCT02306837 -
Consolidation Chemotherapy After Autologous Stem Cell Transplantation for Lymphoid Malignancies
|
Phase 2 | |
Completed |
NCT02771470 -
Intestinal Microflora in Lung Cancer After Chemotherapy
|
Phase 1 | |
Completed |
NCT02454673 -
Therapeutic Individualization for Patients With Locally Advanced Gastric and Gastroesophageal Cancer
|
N/A | |
Completed |
NCT02454647 -
Induction Chemotherapy, Chemoradiotherapy and Surgery in Locally Advanced Gastric Cancer Patients
|
N/A | |
Completed |
NCT01432223 -
Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab
|
Phase 2 | |
Completed |
NCT02767388 -
Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery
|
||
Recruiting |
NCT02555592 -
Strategy of Surgical Resection With Adjuvant Therapy for IIIA NSCLC and N2 Disease Only in Subaortic or Paraaortic Level
|
N/A | |
Suspended |
NCT02121405 -
Randomized Trial of Primary Surgery Followed Selective Radiochemotherapy for Rectal Cancer With MRI Negative CRM
|
Phase 3 | |
Recruiting |
NCT02226380 -
FOLFOX6 as Neoadjuvant Chemotherapy in Local Advanced Gastric Cancer
|
Phase 2 | |
Completed |
NCT00911352 -
Cryotherapy Intervention for Docetaxel-induced Nail Toxicities
|
Phase 2/Phase 3 | |
Completed |
NCT03840824 -
Blood Spot Self-administered Test and Assay
|
||
Active, not recruiting |
NCT01490060 -
Fosaprepitant in Patients Receiving Ifosfamide-based Regimen
|
N/A | |
Completed |
NCT02395341 -
The Longitudinal Ovarian Reserve Study
|
N/A | |
Recruiting |
NCT05268991 -
Aging and Frailty Study
|
||
Recruiting |
NCT03885388 -
Combination of Methotrexate(MTX) and Actinomycin(ACTD) in the Low Risk Gestational Trophoblastic Neoplasma (GTN) Patients With Score of 5-6
|
Phase 2/Phase 3 | |
Completed |
NCT02375776 -
Improving Outcomes in Cancer Patients on Oral Anti-Cancer Medications Using a Multi-modal Mobile Health Intervention
|
N/A | |
Enrolling by invitation |
NCT02074241 -
Molecular Markers of Chemosensitivity for Bladder Cancer
|
N/A | |
Recruiting |
NCT02169388 -
Intestinal Microflora in Colorectal Cancer (CRC) After Chemotherapy
|
Phase 1 | |
Completed |
NCT03402295 -
Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation
|
Phase 3 |